Just 24 hours after the announcement of the more than positive data on 32,000 people recruited in the United States, Chile and Peru, the cold shower arrives from the United States: the numbers presented by AstraZeneca, according to what was communicated by the Data and Safety Monitoring Board , an independent control body, al Barda, the National Institutes of Allergy and Infectious Diseases and the company itself, may be out of date, and further investigation will be required.
The planned approval of the fourth vaccine on American soil has been postponed to date, despite the outcome of the study.Two days ago the company issued a statement in which it stated that the vaccine protects everyone (100% of vaccinated) from death and from the risk of severe forms of the disease, 79% from the risk of symptoms, and which is also effective in the over 65 who, in this case, unlike the previous studies, represented 20% of the sample.
Loading…
Furthermore – and Anthony Fauci himself was very clear on this – an in-depth and specific analysis would not have raised doubts about safety and, in particular, thrombo-embolic risks, while it would have confirmed the efficacy on variants. in circulation in the three countries.
However, so far, the data have not been published in scientific journals, and are therefore not available to the scientific community for independent evaluations. Also given the numbers obtained in vaccinations in Great Britain and Europe, it is unlikely that the most up-to-date data requiring the US authorities deviate a lot from those announced, but so be it.
For now, the US authorities urgently require close cooperation with AstraZeneca, to clear up any doubts, before proceeding with the approval process.